SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

4 marketing jobs

Diasorin logo
3 weeks ago

Director, Global Marketing Immuno

Diasorin

Stillwater, MN (Unknown)Full time$109K/yr – $208K/yr
Diasorin logo
3 months ago

Senior Product Marketing Manager

Diasorin

Austin, TX (On-site)Full time
Diasorin logo
5 months ago

Director, Marketing Communications

Diasorin

Austin, TX (On-site)Full time
Diasorin logo
6 months ago

Global Marketing Copywriter

Diasorin

Austin, TX (On-site)Full time

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

4 jobs
Diasorin logo

Director, Global Marketing Immuno

Diasorin

Stillwater, MN (Unknown)

$109K/yr - $208K/yrIn-houseFull-timeDirector/executive7+ years exp.
3 weeks ago
Diasorin logo

Senior Product Marketing Manager

Diasorin

Austin, TX (On-site)

In-houseFull-timeSenior level10+ years exp.
3 months ago
Diasorin logo

Director, Marketing Communications

Diasorin

Austin, TX (On-site)

In-houseFull-timeDirector/executive
5 months ago
Diasorin logo

Global Marketing Copywriter

Diasorin

Austin, TX (On-site)

In-houseFull-timeMid level3+ years exp.
6 months ago
Diasorin logo
Diasorin

Director, Global Marketing Immuno

Stillwater, MN (Unknown)

$109K/yr – $208K/yrDirector/Executive7+ years expFull time

Posted 3 weeks ago

  • Job
  • Company
  • Salaries
  • People
  • Audience
  • News
  • Links

Job Summary

Own and execute the global Immuno marketing strategy and program development, shaping the franchise vision and driving sustainable growth through cross-functional leadership and customer-driven insights.

  • Define and lead the Immuno strategy and global program
  • Align commercial, scientific, and product development teams around the voice of the customer

Job Description

Responsibilities

  • The Global Marketing Director Immuno will lead the Marketing strategy, including launching with excellence and engaging with customers, bringing voice of customer as lead with other stakeholders across Diasorin’s scientific, commercial, product development teams, project leaders and technical staff.
  • He / She will define and lead the immuno strategy, plan and execute the global program to develop and grow the Immuno franchise.
  • Through collaboration and partnership internally and externally, she/he will drive organizational direction for Diasorin’s commercial leaders and drive financial and strategic initiatives.
  • The Global Marketing Director Immuno is responsible for leading the strategic development and long-term growth of Diasorin's Immuno and Infectious Diseases franchise globally.
  • As a key member of the Global Marketing organization, the role defines the franchise vision, identifies market opportunities, and drives cross-functional alignment across commercial, scientific, and product development functions.
  • Through a strong customer and market focus, the role ensures the delivery of sustainable business growth, portfolio value creation, and competitive leadership within the immunodiagnostics landscape.

Requirements

  • B.S. in Science or Marketing, MBA is desirable
  • 7+ years of marketing experience in a healthcare related business
  • Experience marketing in pharma or companion diagnostics. You are open also to broader In-vitro Diagnostic or Medical Device sectors
  • Able to interact effectively in a matrix organization where commercial areas steer regional Marketing
  • He/She must speak English, Italian is a plus
  • Pharma Marketing and/or Laboratory experience is a plus (i.e. lab tech)
  • Project management experience is a plus
  • Experience with Infectious disease or Immunology or Diagnostic areas

Preferred

  • MBA is desirable
  • Italian is a plus
  • Project management experience is a plus
  • Pharma Marketing and/or Laboratory experience is a plus
  • Experience in Infectious disease or Immunology or Diagnostic areas (beyond core requirements)

Benefits

  • comprehensive plan of health benefits, retirement and financial wellbeing, time off programs, wellbeing support and perks. Benefits may vary by role, country, region, union status, and other employment status factors.
Diasorin logo

Diasorin

Headquartered in Italy and listed on the Italian Stock Exchange within the FTSE MIB Index, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field and, since 2021, has been active in the Life Science business. For over 50 years, the Company has been developing, producing, and marketing reagent kits used by diagnostic laboratories worldwide.The Group operates across five continents through 35 companies, 4 branches, 10 manufacturing facilities, and 9 research and development centers. Our extensive diagnostic testing and life science offering, continuously enhanced through significant investments in research, positions Diasorin as the player with the broadest range of specialty tests available in the diagnostic market, identifying the Group as “The Diagnostic Specialist.”With a team of over 3,200 employees worldwide, including more than 400 researchers, we are committed to improving healthcare and enhancing people's quality of life. We value diversity, skills, and talent as key drivers of innovation and excellence, fostering an inclusive work environment that evolves alongside the ever-changing landscape of global healthcare.

Founded in 1968
Salasco, Piedmont, ITA
2.6K employees (92 in marketing)
www.diasorin.com

Salaries

Posted range

$109K/yr – $208K/yr

Taken straight from the job posting.

See all Diasorin salaries

Marketing Team

Marketing Team Size
86 (3% of company)
Median Career Experience
11 years
Median Tenure
2.4 years
Marketing Roles Posted (Last 30 Days)
1

Traffic Signals

Monthly Visitors
77K
Traffic Source Mix
Search
43%
Direct
40.6%
Referral
8.3%
Social
6.7%
Paid
1.3%

Headcount Trend

Current headcount: ~2.6K

Recent News

Analisi prezzi azioni italiane: Diasorin, Leonardo, Eni
Oct 13, 2025 • FXEmpire
Diasorin trasforma il Service globale: verso un ecosistema intelligente e predittivo
Oct 10, 2025 • cmimagazine.it
Diasorin, perché Deutsche Bank taglia il target price in attesa della trimestrale. Le stime
Oct 8, 2025 • Milano Finanza
Piazza Affari: andamento sostenuto per DiaSorin
Oct 1, 2025 • Teleborsa
Diasorin trasforma il Service con Salesforce
Sep 30, 2025 • TecnoMedicina
Diasorin lancia un nuovo test. Azione sui minimi del 2025 in borsa: ecco perché il mercato sbaglia
Sep 19, 2025 • Milano Finanza
Piazza Affari: andamento sostenuto per DiaSorin
Sep 17, 2025 • Teleborsa
UBS promuove DiaSorin a "buy" e alza il target a €98 sulle prospettive di crescita al 2026
Sep 17, 2025 • Investing.com
Diasorin sale con upgrade Ubs a ‘Buy’ e migliore target prezzo
Sep 17, 2025 • Il Sole 24 ORE
Azioni Diasorin sono da comprare? UBS lancia view bullish, trader ci credono
Sep 17, 2025 • Borsainside
Milano la sola ribassista; DiaSorin best performer
Sep 17, 2025 • MarketScreener Italia
Diasorin - Prezzo sui minimi dal gennaio 2019
Sep 15, 2025 • Websim
Diasorin e Interpump entrano nell'indice MIB ESG
Sep 12, 2025 • Borsa Italiana
Diasorin e Interpump entrano nell'indice MIB ESG
Sep 12, 2025 • Teleborsa
Mad for Science: Al Via le Candidature per il Concorso della Fondazione Diasorin Ets sul Tema Risorse Naturali e Salute
Sep 11, 2025 • EduNews24
Piazza Affari: movimento negativo per DiaSorin
Sep 4, 2025 • La Stampa
Diasorin, prese di beneficio alimentate da JP Morgan
Aug 27, 2025 • orafinanza.it
Diasorin: Ombre sulla Crescita e sulla Valutazione - Scopri Subito i Motivi
Aug 27, 2025 • Investing.com
Azioni Diasorin: crollo dopo boom di ieri! Cosa sta succedendo in borsa?
Aug 27, 2025 • Meteofinanza.com
Diasorin colpita dalle prese di beneficio e dal giudizio "underweight" di JPMorgan
Aug 27, 2025 • Il Sole 24 ORE
DiaSorin vola in Borsa dopo promozione a Overweight da Morgan Stanley
Aug 26, 2025 • la Repubblica
DiaSorin vola in Borsa dopo promozione a Overweight da Morgan Stanley
Aug 26, 2025 • Teleborsa
Borsa Milano in calo con banche su incertezza politica Francia, bene Diasorin
Aug 26, 2025 • Yahoo Finanza
Diasorin, Morgan Stanley alza target price. Possibile uscita dal FTSE MIB
Aug 26, 2025 • orafinanza.it
Diasorin in rally in borsa: perché Morgan Stanley promuove l’azione
Aug 26, 2025 • Milano Finanza
Rally delle azioni Diasorin: l’upgrade di Morgan Stanley spinge il titolo in Borsa
Aug 26, 2025 • Benzinga Italia
Azioni Diasorin da sovrappesare? La dritta che fa impazzire i trader
Aug 26, 2025 • Borsainside
Azioni Diasorin: per gli analisti di Rbc Capital il target price è 105 euro, cosa fare
Aug 26, 2025 • Borsa&Finanza
Spunti su Diasorin: occasione d’acquisto secondo Rbc
Aug 14, 2025 • orafinanza.it
Azioni Diasorin: valore giusto è 105 euro? Da RBC assist potente per comprare
Aug 14, 2025 • Borsainside
Azioni Diasorin: nuovi minimi in arrivo dopo i dati semestrali?
Aug 4, 2025 • Investire.biz
Diasorin, ricavi in crescita a 619 milioni e guidance confermata
Aug 1, 2025 • la Repubblica
Diasorin - Transizione e cautela: prospettive di crescita
Aug 1, 2025 • Websim
Diasorin, più dividendi per i Denegri dalla cassaforte Finde
Aug 1, 2025 • Milano Finanza
Diasorin: impatto stimato dazi su marginalita' 2025 "non significativo"
Jul 31, 2025 • Il Sole 24 ORE
Diasorin, ricavi e margini in crescita nel semestre. Confermata guidance 2025
Jul 31, 2025 • la Repubblica
Diasorin, nel primo semestre crescono ricavi e utile netto. Sprint delle vendite in Nord America
Jul 31, 2025 • Milano Finanza
Diasorin - Richiesta di autorizzazione FDA per LIAISON NES®
Jul 2, 2025 • Websim
Diasorin: il super test Liaison Nes attende il via libera della Fda
Jul 2, 2025 • Milano Finanza
Diasorin: perché è importante l’ok della Fda al pannello per la diagnosi delle infezioni del sangue, il Liaison Plex
Jun 9, 2025 • Milano Finanza
Diasorin in rialzo dopo l'ok Fda al pannello su diagnosi di infezioni del sangue
Jun 9, 2025 • Il Sole 24 ORE
Louder (part of SG Company) consolida la sua presenza nel mercato della diagnostica internazionale: firmata per Diasorin l’area espositiva a ESCMID Global 2025
May 12, 2025 • mediakey.it
Diasorin: nel primo trimestre fatturato in crescita dell’8% e margine EBITDA al 34%
May 6, 2025 • TecnoMedicina
Dividendo Diasorin 2025: ammontare e stacco
May 2, 2025 • orafinanza.it
Diasorin, la trimestrale in arrivo scalda le previsioni del mercato
Apr 29, 2025 • Morningstar Canada
DiaSorin, ok da soci a bilancio e dividendo. Eletto nuovo CdA
Apr 28, 2025 • la Repubblica
Azioni Diasorin: il pharma limita i danni in Borsa dopo i dazi Usa
Apr 14, 2025 • Borsa&Finanza
Il pharma italiano limita i danni in borsa dopo i dazi, le prospettive di Diasorin e Recordati per gli analisti
Apr 7, 2025 • Milano Finanza
Borse oggi in diretta | Il Ftse Mib travolto dai dazi: -6,5%. Crollano banche e Leonardo, tra le blue chip resiste solo Diasorin
Apr 4, 2025 • Milano Finanza
Diasorin ottiene l’annullamento della sanzione amministrativa di Consob: tutti i legali
Mar 17, 2025 • Legalcommunity
Diasorin: approvati i risultati dell’esercizio 2024
Mar 14, 2025 • TecnoMedicina
Diasorin, nel 2024 ricavi e utili in netta crescita. Proposto dividendo a 1,2 euro
Mar 14, 2025 • la Repubblica
Diasorin: utile netto 2024 a 187 mln (+18%), ricavi +3% e cedola di 1,2 euro
Mar 14, 2025 • Il Sole 24 ORE
Diasorin, nel 2024 utile in crescita del 18%. Per i soci cedola di 1,2 euro per azione, ma il titolo frena
Mar 14, 2025 • Milano Finanza
Cosa aspettarsi dalla trimestrale Diasorin dopo la recente volatilità?
Mar 10, 2025 • Morningstar Canada
DiaSorin, promozione a Buy da Stifel con aumento target price
Feb 12, 2025 • Teleborsa
Fondazione Diasorin accreditata dal ministero dell'Istruzione e del merito come ente formatore
Feb 6, 2025 • AboutPharma
«Per Diasorin le valutazioni sono attraenti»
Jan 22, 2025 • Il Sole 24 ORE
Azioni Diasorin, calendario finanziario 2025: trimestrali, assemblea azionisti
Jan 21, 2025 • orafinanza.it
DiaSorin: il calendario e date stacco dividendi 2025
Jan 9, 2025 • Investire.biz
Diasorin in calo, Ubs rivede la valutazione da "buy" a "neutral"
Nov 26, 2024 • Il Sole 24 ORE

Links

www.diasorin.comLinkedInX (Twitter)